ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
68
Elevar Therapeutics and Tanner Pharma Group announce Global Named Patient Program to provide access to Apealea®
admin
2020.07.28
67
Replicate Bioscience and ITI Form Collaboration to Combat Infectious Diseases and Cancers
admin
2020.06.25
66
Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II
admin
2020.06.12
65
Elevar to accept Dr. Gelder for global clinical and marketing
admin
2020.05.26
64
HLB Chairman Jin Yang-gon reveals his ambition to take a global pharma
admin
2020.05.19
63
HLB Rivoceranib’s Clinical Results were 'Excellent' in Cervical Cancer, NSCLC, and Soft Tissue Sarcoma
admin
2020.05.14
62
HLB announces 16 clinical results of Rivoceranib at ASCO
admin
2020.05.14
61
Report from Hanyang Securities on HLB
admin
60
Elevar Therapeutics acquires Global Rights to European approved Apealea® from Oasmia Pharmaceutical
admin
59
JAMA announces Rivoceranib's NSCLC combination therapy
admin
2020.04.27
1
2
3
4
5
6
7
8
9
10
>
>>